ACM
AVXL icon

Aster Capital Management’s Anavex Life Sciences AVXL Stock Holding History

Aster Capital Management’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-288
Closed -$2.47K – 852
2026
Q1 		$2.47K Buy
+288
New +$1.25K ﹤0.01% 746

Other funds holding AVXL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SF
Summit Financial Parsippany, New Jersey $9.12B AUM 27.44% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Aster Capital Management's AVXL Position: Q2 2026 in Review

Aster Capital Management sold out of Anavex Life Sciences (AVXL) in Q2 2026, closing a stake of 288 shares — an estimated $2.47K sold.

Aster Capital Management first reported a position in AVXL in Q1 2026 and held it in 1 quarter. The position peaked at $2.47K in Q1 2026. 179 funds tracked by Wall St. Rank hold AVXL as of Q2 2026.

  • Aster Capital Management reported no remaining Anavex Life Sciences position as of Q2 2026 after selling out during the quarter.
  • Aster Capital Management sold 288 Anavex Life Sciences shares in Q2 2026, an estimated $2.47K.
  • Aster Capital Management first reported a position in Anavex Life Sciences in Q1 2026 and held it in 1 quarter.
  • Aster Capital Management's Anavex Life Sciences position peaked at $2.47K in Q1 2026.
  • 179 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q2 2026.

Based on Aster Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.